16635275

Source:http://linkedlifedata.com/resource/pubmed/id/16635275

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002895, umls-concept:C0015780, umls-concept:C0030705
pubmed:issue	5
pubmed:dateCreated	2006-4-25
pubmed:abstractText	Seventy-two thousand Americans are homozygous for the sickle cell gene and 2 million are carriers. The gene offers protection against malaria but can be a cause of chronic pain and early death. Life expectancy is 48 years for females. Some people with sickle cell anemia live into their 60s and beyond. The purpose of this article is to review and summarize evidence from clinical, translational, and epidemiologic studies that have examined the clinically relevant aspects of sickle cell anemia as it relates to the female patient. Studies were identified through a MEDLINE search for articles in English between the years 1966 and 2005. References from identified reports were also used to identify additional articles. Women with sickle cell disease experience multiple complications. These complications can affect each and every organ system and are often worse in pregnant women. Progestins, hydroxyurea, and bone marrow transplant appear to ameliorate sickle cell anemia. Other therapies being evaluated include those that increase fetal hemoglobin concentration and prevent dehydration of the sickle red blood cells. More than one third of pregnancies in women with sickle syndromes terminate in abortion, stillbirth, or neonatal death. Recently, a number of genes modifying the clinical severity of sickle cell anemia have been identified. Sickle anemia is associated with immense suffering and multisystemic complications. In addition to the now-established therapy with hydroxyurea and bone marrow transplants, there are multiple investigational treatments that offer the hope of extending life expectancy while diminishing associated morbidities. Whether any of these new agents are safe in pregnancy has yet to be determined. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING OBJECTIVES: After completion of this article, the reader should be able to summarize the multiple complications that women with sickle cell anemia (SCA) endure, explain that many of the complications worsen during pregnancy and increase the risk of an adverse pregnancy outcome, and state that there are treatment modalities that extend life and diminish morbidities.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0401007
pubmed:citationSubset	IM
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0029-7828
pubmed:author	pubmed-author:Dauphin-McKenzieNathalieN, pubmed-author:GillesJerry MJM, pubmed-author:HarringtonThomasT, pubmed-author:JacquesElvireE
pubmed:issnType	Print
pubmed:volume	61
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	343-52
pubmed:meshHeading	pubmed-meshheading:16635275-Anemia, Sickle Cell, pubmed-meshheading:16635275-Female, pubmed-meshheading:16635275-Humans, pubmed-meshheading:16635275-Pregnancy, pubmed-meshheading:16635275-Pregnancy Complications, Hematologic
pubmed:year	2006
pubmed:articleTitle	Sickle cell anemia in the female patient.
pubmed:affiliation	Department of Obstetrics and Gynecology, University of Miami-Jackson Memorial Hospital, Miami, Florida, USA. ndauphin@um-jmh.org
pubmed:publicationType	Journal Article, Review